Wegovy Maker Launches Lower-Cost Subscription Plans

Key TakeawaysThe company behind the popular weight loss drug Wegovy has announced lower costsPatients can save up to $1,200 a year with new subscription optionsThe subscriptions are for those paying out of pocket.THURSDAY, April 2, 2026 (HealthDay News) — A popular weight loss drug may soon be more affordable for some people.Danish pharmaceutical company Novo Nordisk has launched a subscription program for its obesity treatment Wegovy, offering lower and more predictable monthly prices.The program is aimed at those who pay for the medication themselves, The Wall Street Journal reported.Patients can choose from three-, six- or 12-month plans for the Wegovy injection and two higher-dose pill versions.Monthly costs for the injection drop to:$329 per month for a three-month subscription$299 per month for six months$249 per month for a 12-month subscriptionThat's about $1,200 in yearly savings on the longest plan, the company said.The pill version is a bit cheaper:$289 per month for a three-month subscription$269 per month for six months$249 per month for a year’s subscriptionThat could save patients up to $600 a year.The program is available through telehealth platforms including Ro, WeightWatchers and LifeMD.More providers like Hims & Hers and Sesame are expected to come online soon.Novo Nordisk said the goal is to make costs more predictable and help people stay on treatment."The program is designed to reduce cost uncertainty and help people start and stay on [the] FDA-approved obesity treatment," the company said.The subscription plans come as competition grows in the weight-loss medication market. Rival drugmaker Eli Lilly, whose pill secured FDA approval in only 50 days, sells its weight loss injectable Zepbound for about $299 to $449 a month, The Wall Street Journal added.Drugmakers are also facing pressure from cheaper copycat versions sold by compounding pharmacies.Novo Nordisk has said it plans to lower U.S. prices for Wegovy and its diabetes drug Ozempic starting next year, as it tries to reach more patients.More informationThe National Academy of Medicine has more on GLP-1 drugs.SOURCE: The Wall Street Journal, March 31, 2026.What This Means For YouNew pricing may make weight loss drugs more affordable for people who pay for them out of pocket..Sign up for our weekly HealthDay newsletter

Wegovy Maker Launches Lower-Cost Subscription Plans

Related Stories